(Q46887502)

26 December 2017

title

Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide (English)

1 reference

26 December 2017

author

Peter J. Trainer

8

1 reference

26 December 2017

author name string

N Karavitaki

1

1 reference

26 December 2017

H E Turner

2

1 reference

26 December 2017

C B T Adams

3

1 reference

26 December 2017

S Cudlip

4

1 reference

26 December 2017

J V Byrne

5

1 reference

26 December 2017

V Fazal-Sanderson

6

1 reference

26 December 2017

S Rowlers

7

1 reference

26 December 2017

J A H Wass

9

1 reference

26 December 2017

publication date

19 November 2007

1 reference

26 December 2017

published in

Clinical Endocrinology

1 reference

26 December 2017

volume

68

1 reference

26 December 2017

issue

6

1 reference

26 December 2017

page(s)

970-975

1 reference

26 December 2017

Medical progress: Acromegaly

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03139.X

Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03139.X

The importance of locating a good pituitary surgeon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03139.X

Octreotide as primary therapy for acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03139.X

Primary medical therapy for acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03139.X

Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03139.X

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03139.X

Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03139.X

Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03139.X

Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03139.X

Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03139.X

Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03139.X

First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03139.X

10.1111/J.1365-2265.2007.03139.X

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

18031313

1 reference

26 December 2017